Combining miR-10b-targeted nanotherapy with low-dose doxorubicin elicits durable regressions of metastatic breast cancer

Byunghee Yoo, Amol Kavishwar, Alana Ross, Ping Wang, Doris P. Tabassum, Kornelia Polyak, Natalia Barteneva, Victoria Petkova, Pamela Pantazopoulos, Aseda Tena, Anna Moore, Zdravka Medarova

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

The therapeutic promise of microRNA (miRNA) in cancer has yet to be realized. In this study, we identified and therapeutically exploited a new role for miR-10b at the metastatic site, which links its overexpression to tumor cell viability and proliferation. In the protocol developed, we combined a miR-10b-inhibitory nanodrug with low-dose anthracycline to achieve complete durable regressions of metastatic disease in a murine model of metastatic breast cancer. Mechanistic investigations suggested a potent antiproliferative, proapoptotic effect of the nanodrug in the metastatic cells, potentiated by a cell-cycle arrest produced by administration of the low-dose anthracycline. miR-10b was overexpressed specifically in cells with high metastatic potential, suggesting a role for this miRNA as a metastasis-specific therapeutic target. Taken together, our results implied the existence of pathways that regulate the viability and proliferation of tumor cells only after they have acquired the ability to grow at distant metastatic sites. As illustrated by miR-10b targeting, such metastasis-dependent apoptotic pathways would offer attractive targets for further therapeutic exploration.

Original languageEnglish
Pages (from-to)4407-4415
Number of pages9
JournalCancer Research
Volume75
Issue number20
DOIs
Publication statusPublished - Oct 15 2015
Externally publishedYes

Fingerprint

Doxorubicin
Anthracyclines
Breast Neoplasms
MicroRNAs
Cell Proliferation
Neoplasm Metastasis
Neoplasms
Cell Cycle Checkpoints
Cell Survival
Therapeutics

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Yoo, B., Kavishwar, A., Ross, A., Wang, P., Tabassum, D. P., Polyak, K., ... Medarova, Z. (2015). Combining miR-10b-targeted nanotherapy with low-dose doxorubicin elicits durable regressions of metastatic breast cancer. Cancer Research, 75(20), 4407-4415. https://doi.org/10.1158/0008-5472.CAN-15-0888

Combining miR-10b-targeted nanotherapy with low-dose doxorubicin elicits durable regressions of metastatic breast cancer. / Yoo, Byunghee; Kavishwar, Amol; Ross, Alana; Wang, Ping; Tabassum, Doris P.; Polyak, Kornelia; Barteneva, Natalia; Petkova, Victoria; Pantazopoulos, Pamela; Tena, Aseda; Moore, Anna; Medarova, Zdravka.

In: Cancer Research, Vol. 75, No. 20, 15.10.2015, p. 4407-4415.

Research output: Contribution to journalArticle

Yoo, B, Kavishwar, A, Ross, A, Wang, P, Tabassum, DP, Polyak, K, Barteneva, N, Petkova, V, Pantazopoulos, P, Tena, A, Moore, A & Medarova, Z 2015, 'Combining miR-10b-targeted nanotherapy with low-dose doxorubicin elicits durable regressions of metastatic breast cancer', Cancer Research, vol. 75, no. 20, pp. 4407-4415. https://doi.org/10.1158/0008-5472.CAN-15-0888
Yoo, Byunghee ; Kavishwar, Amol ; Ross, Alana ; Wang, Ping ; Tabassum, Doris P. ; Polyak, Kornelia ; Barteneva, Natalia ; Petkova, Victoria ; Pantazopoulos, Pamela ; Tena, Aseda ; Moore, Anna ; Medarova, Zdravka. / Combining miR-10b-targeted nanotherapy with low-dose doxorubicin elicits durable regressions of metastatic breast cancer. In: Cancer Research. 2015 ; Vol. 75, No. 20. pp. 4407-4415.
@article{d8a1436f264b4858b18bef80c2533b50,
title = "Combining miR-10b-targeted nanotherapy with low-dose doxorubicin elicits durable regressions of metastatic breast cancer",
abstract = "The therapeutic promise of microRNA (miRNA) in cancer has yet to be realized. In this study, we identified and therapeutically exploited a new role for miR-10b at the metastatic site, which links its overexpression to tumor cell viability and proliferation. In the protocol developed, we combined a miR-10b-inhibitory nanodrug with low-dose anthracycline to achieve complete durable regressions of metastatic disease in a murine model of metastatic breast cancer. Mechanistic investigations suggested a potent antiproliferative, proapoptotic effect of the nanodrug in the metastatic cells, potentiated by a cell-cycle arrest produced by administration of the low-dose anthracycline. miR-10b was overexpressed specifically in cells with high metastatic potential, suggesting a role for this miRNA as a metastasis-specific therapeutic target. Taken together, our results implied the existence of pathways that regulate the viability and proliferation of tumor cells only after they have acquired the ability to grow at distant metastatic sites. As illustrated by miR-10b targeting, such metastasis-dependent apoptotic pathways would offer attractive targets for further therapeutic exploration.",
author = "Byunghee Yoo and Amol Kavishwar and Alana Ross and Ping Wang and Tabassum, {Doris P.} and Kornelia Polyak and Natalia Barteneva and Victoria Petkova and Pamela Pantazopoulos and Aseda Tena and Anna Moore and Zdravka Medarova",
year = "2015",
month = "10",
day = "15",
doi = "10.1158/0008-5472.CAN-15-0888",
language = "English",
volume = "75",
pages = "4407--4415",
journal = "Journal of Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "20",

}

TY - JOUR

T1 - Combining miR-10b-targeted nanotherapy with low-dose doxorubicin elicits durable regressions of metastatic breast cancer

AU - Yoo, Byunghee

AU - Kavishwar, Amol

AU - Ross, Alana

AU - Wang, Ping

AU - Tabassum, Doris P.

AU - Polyak, Kornelia

AU - Barteneva, Natalia

AU - Petkova, Victoria

AU - Pantazopoulos, Pamela

AU - Tena, Aseda

AU - Moore, Anna

AU - Medarova, Zdravka

PY - 2015/10/15

Y1 - 2015/10/15

N2 - The therapeutic promise of microRNA (miRNA) in cancer has yet to be realized. In this study, we identified and therapeutically exploited a new role for miR-10b at the metastatic site, which links its overexpression to tumor cell viability and proliferation. In the protocol developed, we combined a miR-10b-inhibitory nanodrug with low-dose anthracycline to achieve complete durable regressions of metastatic disease in a murine model of metastatic breast cancer. Mechanistic investigations suggested a potent antiproliferative, proapoptotic effect of the nanodrug in the metastatic cells, potentiated by a cell-cycle arrest produced by administration of the low-dose anthracycline. miR-10b was overexpressed specifically in cells with high metastatic potential, suggesting a role for this miRNA as a metastasis-specific therapeutic target. Taken together, our results implied the existence of pathways that regulate the viability and proliferation of tumor cells only after they have acquired the ability to grow at distant metastatic sites. As illustrated by miR-10b targeting, such metastasis-dependent apoptotic pathways would offer attractive targets for further therapeutic exploration.

AB - The therapeutic promise of microRNA (miRNA) in cancer has yet to be realized. In this study, we identified and therapeutically exploited a new role for miR-10b at the metastatic site, which links its overexpression to tumor cell viability and proliferation. In the protocol developed, we combined a miR-10b-inhibitory nanodrug with low-dose anthracycline to achieve complete durable regressions of metastatic disease in a murine model of metastatic breast cancer. Mechanistic investigations suggested a potent antiproliferative, proapoptotic effect of the nanodrug in the metastatic cells, potentiated by a cell-cycle arrest produced by administration of the low-dose anthracycline. miR-10b was overexpressed specifically in cells with high metastatic potential, suggesting a role for this miRNA as a metastasis-specific therapeutic target. Taken together, our results implied the existence of pathways that regulate the viability and proliferation of tumor cells only after they have acquired the ability to grow at distant metastatic sites. As illustrated by miR-10b targeting, such metastasis-dependent apoptotic pathways would offer attractive targets for further therapeutic exploration.

UR - http://www.scopus.com/inward/record.url?scp=84945559162&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84945559162&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-15-0888

DO - 10.1158/0008-5472.CAN-15-0888

M3 - Article

VL - 75

SP - 4407

EP - 4415

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0008-5472

IS - 20

ER -